Classification and management of anaplastic gliomas

Current Opinion in Neurology

Volumn 22, Issue 6, 2009, Pages 650-656

  Wick, Wolfgang ^a   Weller, Michael ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

1p 19q; O6 methyl guanyl methyltransferase; Anaplastic gliomas; Isocitrate dehydrogenase 1

Indexed keywords

AMINOLEVULINIC ACID; BEVACIZUMAB; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; ENZASTAURIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; IRINOTECAN; ISOCITRATE DEHYDROGENASE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; TEMOZOLOMIDE; TEMSIROLIMUS; VATALANIB; VINCRISTINE;

BRAIN SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHROMOSOME 19Q; CHROMOSOME 1P; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DNA METHYLATION; GLIOBLASTOMA; HUMAN; MULTIPLE CYCLE TREATMENT; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVER VARIATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL; REVIEW;

BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DRUG THERAPY; GLIOMA; HUMANS; RADIOTHERAPY;

EID: 74049141730     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3283329ce7     Document Type: Review

References (51)

1. Chang SM, Nelson S, Vandenberg S, et al. Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. J Neurooncol 2009; 92:401-415.
2. Van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastro-cytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006; 24:2715-2722.
3. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006; 24:2707-2714.
4. Wick W, Hartmann C, Engel C, et al. for the Neurooncology Working Group (NOA) of the German Cancer Society. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolo-mide. J Clin Oncol (in press).
5. Glioma Meta-analysis Trialists (GMT) Group. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359:1011-1018.
6. Neuro-Oncology Working Group (NOA) of the German Cancer Society. Neuro-Oncology Working Group (NOA)-01 trial of ACNU/VM26 versus ACNU/Ara-C chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol 2003; 21:3276-3284.
7. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-996.
8. Stummer W, Pichlmeier U, Meinel T, et al., ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7:392-401.
9. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90:1473-1479.
10. Stupp R, Dietrich P-Y, Kraljevic SO, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002; 20:1375-1382.
11. Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effect of radio-therapies in patients with low-grade glioma: long-term follow-up. Lancet Neurol 2009; 8:810-818.
12. Szeto MD, Chakraborty G, Hadley J, et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res 2009; 69:4502-4509.
13. Wick W, Stupp R, Beule A-C, et al. A novel tool to analyse MRI recurrence patterns in glioblastoma. Neuro Oncol 2008; 10:1019-1024.
14. Hegi ME, Diserens A-C, Gorlia T, et al. MGMTgene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352:997-1003.
15. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353:2012-2024.
16. Weller M, Berger H, Hartmann C, et al. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res 2007; 13:6933-6937.
17. Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006; 65:988-994.
18. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006; 66:9852-9861.
19. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004; 4:296-307.
20. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148-1159.
21. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 10:1871-1874.
22. Herrlinger U, Rieger J, Koch D, et al. UKT-03 phase II trial of CCNU plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma. J Clin Oncol 2006; 24:4412-4417.
23. Weller M, Felsberg J, Hartmann C, et al. for the German Glioma Network. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma. A prospective translational study of the German Glioma Network. J Clin Oncol (in press).
24. Kouwenhoven MCM, Gorlia T, Kros JM, et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro Oncol 2009 [Epub ahead of print]
25. Kros JM, Gorlia T, Kouwenhoven MC, et al. Panel review of anaplastic oligodendroglioma from EORTC trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss and correlations with outcome. J Neu-ropathol Exp Neurol 2007; 66:545-551.
26. Giannini C, Burger PC, Berkey BA, et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 2008; 18:360-369.
27. Tabatabai G, Frank B, Wick A, et al. Synergistic antiglioma activity of radio therapy and enzastaurin. Ann Neurol 2007; 61:153-161.
28. Wick W, Puduvalli VK, Chamberlain M, et al. Enzastaurin versus lomustine in the treatment of recurrent intracranial glioblastoma: a phase III study. J Clin Oncol (in press).
29. van den Bent MJ, DubbinkHJ, Sanson M, etal. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group study 26951. J Clin Oncol (in press).
30. Miller CR, Dunham CP, Scheithauer BW, et al. Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 2006; 24: 5419-5426.
31. Burger PC. What is an oligodendroglioma? Brain Pathol 2002; 12:257-259.
32. Brandes AA,Tosoni A, CavalloG, etal.Temozolomide 3 weekson and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from Gruppo Italiano Cooperativo din Euro-Oncologia (GICNO). Br J Cancer 2006; 95:1155-1160.
33. Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008; 116:597-602.
34. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321:1807-1811.
35. Wick A, Pascher C, Wick W, et al. Rechallenge with temozolomide in recurrent gliomas. J Neurol 2009; 256:734-741.
36. Yan H, Parsons DW, Jin G, etal. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360:765-773.
37. Quon H, Abdulkarim B. Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev 2008:CD007104.
38. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13:1253-1259.
39. Cloughesy TF, Prados MD, Mikkelsen T, et al. A phase II, randomized, noncomparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) [abstract]. J Clin Oncol 2008; 26 (15S):2010b.
40. Hildebrand J, Gorlia T, Kros JM, et al., EORTC Brain Tumour Group inves-tigators. Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). Eur J Cancer 2008; 44:1210-1216.
41. Omuro AM. Exploring multitargeting strategies for the treatment of gliomas. Curr Opin Investig Drugs 2008; 9:1 287-1295.
42. Weiler M, Hartmann C, Weiwrodt D, etal. Phase II trial of radiochemotherapy with daily concomitant and adjuvant intensified (one week on/one week off) temozolomide plus indomethacin in newly diagnosed glioblastoma: UKT-05. Int J Radiat Oncol Biol Phys (in press).
43. Whyte L, Hodecker S, Weiler M, Wick W. Challenges in diagnosis and treatment of recurrent glioma: novel compounds and therapeutic use of stem cells. Onkopipeline 2009; 2:23-29.
44. Butowski N, Lamborn KR, Lee BL, et al. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol 2009; 91:183-189.
45. Wick W, Steinbach JP, Küker WM, et al. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 2004; 62:2113-2115.
46. Wick A, Felsberg J, Steinbach JP, et al. Efficacy and tolerability of temozo-lomide in an one week on/one week off regimen in patients with recurrent glioma. J Clin Oncol 2007; 25:3357-3361.
47. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:1277-1280.
48. Grant R, Liang BC, Slattery J, et al. Chemotherapy response criteria in malignant glioma. Neurology 1997; 48:1336-1340.
49. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol 2006; 24:1281-1288.
50. Desjardins A, Reardon DA, Herndon JE 2nd, et al. Bevacizumab plus irino-tecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008; 14:7068-7073.
51. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol 2009; 11 8:469-474.